Loading...
•
Sep 30, 2023
ProKidney Q3 2023 Earnings Report
Reported third quarter financial results
Key Takeaways
ProKidney reported having nearly $400 million in cash, cash equivalents and marketable securities as of September 30, 2023, and expects cash to fund operations into the fourth quarter of 2025. Research and development expenses were $32.2 million and general and administrative expenses were $14.4 million for the three months ended September 30, 2023. Net loss before noncontrolling interest was $42.0 million for the three months ended September 30, 2023.
Cash, cash equivalents and marketable securities totaled $396.3 million as of September 30, 2023.
Cash is expected to fund operations into the fourth quarter of 2025.
Research and development expenses were $32.2 million for the three months ended September 30, 2023.
Net loss before noncontrolling interest was $42.0 million for the three months ended September 30, 2023.
Forward Guidance
ProKidney expects that existing cash, cash equivalents and marketable securities held at September 30, 2023, will enable funding of operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Positive Outlook
- Existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...